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Summary. Network meta-analysis (NMA) pools evidence on multiple treatments to estimate
relative treatment effects. Included studies are typically assessed for risk of bias; however, this
provides no indication of the impact of potential bias on a decision based on the NMA. We
propose methods to derive bias adjustment thresholds which measure the smallest changes
to the data that result in a change of treatment decision. The methods use efficient matrix
operations and can be applied to explore the consequences of bias in individual studies or
aggregate treatment contrasts, in both fixed and random-effects NMA models. Complex models
with multiple types of data input are handled by using an approximation to the hypothetical
aggregate likelihood.The methods are illustrated with a simple NMA of thrombolytic treatments
and a more complex example comparing social anxiety interventions. An accompanying R
package is provided.
Keywords: Evidence synthesis; Influence matrix; Mixed treatment comparison; Quality of
evidence; Risk of bias; Threshold analysis
1. Introduction
Network meta-analysis (NMA) compares the relative effectiveness of multiple treatments by
combining the evidence from randomized controlled trials (RCTs), each of which compares
only a subset of the treatments of interest (Lumley, 2002; Caldwell et al., 2005; Lu and Ades,
2006). NMA is increasingly being used by policy makers to inform treatment recommendations.
However, if some of the trials included are biased then there is a risk that results from the NMA
will also be biased, which could lead to suboptimal treatment recommendations.
There are numerous reasons why results from RCTs may be biased with respect to the tar-
get population for decision making, which are typically dichotomized into issues of ‘internal
validity’, including poor study design or conduct, e.g. inadequate randomization or blinding,
or loss to follow-up (Schulz et al., 1995; Savovic et al., 2012a,b), and issues of ‘external valid-
ity’, affecting generalization to or representativeness of the target population (Rothwell, 2005).
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The potential for bias in an individual study can be assessed qualitatively by using methods
such as the Cochrane risk-of-bias tool (Higgins et al., 2011). The ‘Grading of recommendations
assessment, development and evaluation’ (GRADE) framework (Guyatt et al., 2011) can also
be used to give an indication of the reliability of the evidence informing a pairwisemeta-analysis.
Recently, two methods to extend the GRADE framework to NMA have been proposed (Puhan
et al., 2014; Salanti et al., 2014). Although such approaches can produce valuable and necessary
qualitative assessments, they cannot tell how deficiencies in internal or external validity might
affect the treatment recommendation. For example, studies that are rated at high risk of bias due
to issues with internal or external validity that have negligible influence on the treatment recom-
mendation should be of little concern, whereas if they have a larger influence on the treatment
recommendation then they should be scrutinized carefully.
Recently, Caldwell et al. (2016) proposed a method for assessing how adjustment for bias,
either in individual studies or in the combined evidence on treatment contrasts, would affect the
treatment recommendations from an NMA. As a form of ‘threshold analysis’, no assumptions
are made regarding the source or type of bias; nor is any bias to be estimated or adjusted for;
instead, thresholds are derived to show how large potential bias adjustments would need to be
before the base case treatment recommendation changes, and what the new recommendation
would be. The information that is provided by such a threshold analysis is therefore highly
relevant to decisionmakers and guideline developers. Caldwell et al. (2016) described an iterative
numerical method for obtaining bias adjustment thresholds based on a two-stage Bayesian
NMA; however, there are some limitations to this approach. Firstly, the two-stageNMA,where
pairwise meta-analysis is performed in a first step and then each of the pairwise estimates is
combined to give consistentNMAestimates, is only an approximation to the preferred one-stage
NMA where all studies on all comparisons are synthesized at once (Lu et al., 2011). Decision
makers such as the National Institute for Health and Care Excellence recommend the one-stage
method because of its accuracy and convenience when results are used in decision models (Dias
et al., 2013b; National Institute for Health and Care Excellence, 2013, 2014). Secondly, the
numerical method is limited in its flexibility, requires the original data and full model details
to be available to the analyst and can involve lengthy computation times. This paper presents
an approach to threshold analysis that can be readily used by decision makers and guideline
developers but avoids the limitations of the approach that was taken by Caldwell et al. (2016).
We take a Bayesian approach to NMA because it sits naturally within a decision framework,
easily extending to probabilistic cost-effectiveness analysis (CEA) (Dias et al., 2013b). However,
the methods apply naturally to frequentist approaches where the influence matrix is known, or
(at least approximately) by setting the prior precision matrix to 0.
The remainder of this paper is structured as follows. In Section 2 bias adjustment thresh-
olds are derived algebraically and decision invariant bias adjustment intervals are constructed,
which identify precisely how large a bias adjustment can be before the recommended treatment
changes. In Section 3 the method is illustrated with examples and applied to two published
NMAs. Finally, results are discussed and compared with other approaches. Additional mate-
rial, including detailed mathematical derivations and proofs, is provided in a Web appendix.
The programs that were used to analyse the data can be obtained from
http://wileyonlinelibrary.com/journal/rss-datasets
2. Methods
2.1. Network meta-analysis
Suppose that we have data from n studies onK treatments.Without loss of generality, treatment
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1 is set as the reference against which other treatments are compared. Let Aj be the number
of arms in study j ∈ {1, : : : ,n}, so study j contributes Aj − 1 relative effects measures (data
points) of the treatments in arms from 2 toAj, compared with that in arm 1. There are therefore
N=Σnj=1.Aj −1/ data points in total, which are contained in the data vector y= .y1, : : : ,yN/
T
where we assume that any multiple data entries from the same study are arranged contiguously
within y. Each element yi : i∈ {1, : : : ,N} is a relative effect that corresponds to a comparison
between treatment ti and comparator ci (also known).
We assume amultivariate normal likelihood for the data, so y∼N.δ,V/with δ= .δ1, : : : , δN/
T
where the covariance matrix V is assumed known. Studies are assumed independent so that
V=diag.V1, : : : ,Vn/ is block diagonal, whereVj is the .Aj −1/× .Aj −1/ covariancematrix for
study j. If study j has only two treatments (so only one comparison is made between treatments)
then Vj is a single element giving the variance of the corresponding relative effect.
NMA estimates basic relative treatment effect parameters dk, k= 2, : : : ,K, for treatment k
compared with the reference treatment 1, with d1= 0. Contrasts between any two treatments
b and a can then be formed by using the consistency assumptions (Lu and Ades, 2004) as
dab := db − da. We take a Bayesian approach, specifying prior distributions for unknown pa-
rameters and drawing conclusions from the joint posterior distribution. However, all results
follow naturally for frequentist approaches, e.g. by setting the prior precision matrixΣ−1d equal
to 0 (see Section 4). Diffuse normal priors are usually given for the treatment effect parameters;
however, all results that are presented here hold for any multivariate normal prior distribution
d∼N.d0,Σd/, where d= .d2, : : : , dK/
T.
From here, we can proceed in two ways: a fixed effect (FE) model, where all studies on a
treatment contrast estimate the same treatment parameters, or a random-effect (RE) model,
where a degree of heterogeneity is allowed, and studies on a treatment contrast are assumed to
estimate similar treatment parameters froma commondistribution. In anFEmodel, δi=dti −dci
for each i=1, : : : ,N, which can be written concisely in matrix form as follows:
prior, d∼N.d0,Σd/,
likelihood, y|d∼N.δ,V/,
FE model, δ=Xd,
⎫⎪⎬
⎪⎭ .1/
for an appropriate N × .K−1/ design matrix X which picks out the corresponding treatment
parameters for each study contrast; for example, a study contrast comparing treatments 2 and
4 in an NMA of five treatments would have corresponding row in X set to .−1, 0, 1, 0/.
For an REmodel with two-arm trials, δi∼N.dti −dci , τ
2/ for each i=1, : : : ,N. For simplicity
of exposition, we assume that the between-study variance τ2 is homogeneous between all treat-
ment contrasts; however, the derivations are identical with distinct between-study variances for
each contrast. The FE model can be thought of as a special case of the RE model, where the
between-study variance τ2 is set to 0.
If there are trials withmore than two arms, then amultivariate normal distribution is required
to capture the correlations between the estimated relative effects from the same RCT (Higgins
and Whitehead, 1996). In general, the RE model can be written as follows:
prior, d∼N.d0,Σd/, τ ∼pi,
likelihood, y|δ∼N.δ,V/,
RE model, δ|d, τ2∼N.Xd,Στ2/,
⎫⎪⎬
⎪⎭ .2/
with some prior pi on τ (or τ2) such as τ ∼U.0, 10/, and where the between-studies covariance
matrix Στ2 is of the form Aτ
2 where A is a block diagonal ‘design matrix’. Since here τ2 is
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assumed to be the same between all contrasts, the block of A corresponding to a study report-
ing relative effects with three or more arms will have 1s on the diagonal and 0.5s everywhere
else (Higgins andWhitehead, 1996). Note that the between-study variance is assumed homoge-
neous for simplicity only; the derivations proceed identically with a generic covariance matrix
Στ2 .
Although we have considered only data in relative effects form here, all results apply easily to
data in absolute effects (arm level) form (or even mixtures of the two) simply by modifying the
design and covariance matrices appropriately.
2.2. Decision rule
We assume that the decision is made on the basis of the estimated relative treatment effects
from the joint posterior distribution of d2, : : : , dK, and (without loss of generality) we assume
that a larger observed outcome (e.g. log-odds of success) is preferable. The optimal treatment
is chosen to be that which has the highest expected treatment effect, i.e. kÅ which satisfies
Ed|y.dkÆ/Ed|y.dk/,∀ k=1, : : : ,K. For brevity, we write E.·/ in place of Ed|y.·/, so that
kÅ :=argmax
k=1,:::,K
E.dk/: .3/
Note that other decision rules could be considered, e.g. a rule based on a minimally important
difference, or maximizing the expected net benefit from an economic model (see Section 4).
2.3. Deriving bias adjustment thresholds at study level
We begin by considering bias adjustments to individual study estimates of treatment effect one
at a time, i.e. for each data point ym. The methods that are described in this section and Section
2.4 below are repeated for each m∈{1, : : : ,N} separately. In Section 2.5 we extend the methods
to consider bias adjustments for multiple data points.
Suppose that some study data point ym, instead of estimating the true value of dtmcm , is biased
so that it estimates dtmcm − βm. We aim to find threshold values for βm at which the overall
decision based on equation (3) changes. For this we consider hypothetical data that have been
bias adjusted, y˜, on which we could perform the NMA to obtain the ‘true’ treatment effect. We
define the bias-adjusted data as y˜.βm/=y+βm, where the ith component of the vector βm is
[βm]i=
{
βm if i=m
0 if i =m.
∀ i∈{1, : : : ,N} .4/
Weshall denote posterior expectationwith respect to the bias-adjusted data by E˜.·/ :=Ed|y˜.βm/.·/:
2.3.1. General form of bias adjustment thresholds
We wish to find the smallest positive and negative values of the bias adjustment such that
the optimal treatment kÅ given by equation (3) changes; we call these values bias adjustment
thresholds and denote them β+threshm and β
−thresh
m respectively. At each threshold value there is a
new treatment k˜
Å
that achieves the maximum posterior expected treatment effect.
To find the threshold values, we consider a set of K−1 possible solutions {uakÆ,m :a∈{1, : : : ,
K}\kÅ}, where each uakÆ,m reflects the amount of bias adjustment to data point ym required
to change the sign of E.dakÆ/ and to make treatment a more efficacious in expectation than
the current optimal treatment kÅ. The threshold values β+threshm and β
−thresh
m are simply the smal-
lest positive and negative solutions from this set:
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β+threshm =ubkÆ,m b= argmin
a∈{1,:::,K}\kÆ
{uakÆ,m :uakÆ,m >0},
β−threshm =ubkÆ,m b= argmax
a∈{1,:::,K}\kÆ
{uakÆ,m :uakÆ,m <0}:
.5/
The possible solutions uakÆ,m are determined by the expected difference in treatment effects,
−E.dakÆ/, divided by the amount of influence that ym has on the expected difference, given by a
linear combination of elements of the influence matrix H : for kÅ =1
uakÆ,m=
−E.dakÆ/
[H]kÆ−1,m− [H]a−1,m
, for a∈{2, : : : ,K}\kÅ,
u1kÆ,m=
−E.d1kÆ/
[H]kÆ−1,m
, for a=1; .6a/
for kÅ=1
u1a,m=
−E.d1a/
[H]a−1,m
, for a∈{2, : : : ,K}: .6b/
[H]a−1,m is the entry in the .a−1/th row and mth column of H, the influence matrix that maps
the data y onto the posterior estimates of the basic treatment effect parameters d:
E˜.d/=E.d/+Hβ .7/
for any general vector β changing the observed data y to bias-adjusted data y˜.β/=y+β. The
exact form of H will depend on the model and is described in the following sections for some
typicalNMAmodels. The influencematrix is related to the hatmatrix (Konig et al., 2013;Krahn
et al., 2013; Salanti et al., 2014); see Section 4.
The new optimal treatment at the thresholds could be found by using equation (3), which
requires re-evaluating the joint posterior mean and taking a maximum for each β+threshm and
β−threshm . However, lemma 1 (in on-line Appendix A.1) shows that a more efficient approach is
simply to note the newoptimal treatment from the contrast whose posterior expectation changes
sign at the bias adjustment threshold—treatment b from equation (5).
From the positive and negative bias adjustment thresholds, it is intuitive to think of construct-
ing an interval .ym+β
−thresh
m , ym+β
+thresh
m / within which a bias-adjusted value of y˜m can lie
without changing the treatment decision. We refer to such an interval as the decision invariant
bias adjustment interval about ym and visualize this as shown in Fig. 1.
Thresholds and invariant intervals may be derived for more complex treatment decisions, as
well as the simple ‘maximal efficacy’ decisions that were described above. For example, decision
makers may be interested in the level of bias adjustment that would be required tomake another
treatment significantly more effective than the base case optimal treatment, as judged by some
minimal clinically important difference ρ. In this case, the thresholds are found in the usual
Fig. 1. Example construction of a decision invariant bias adjustment interval ( ) for a data point ym, for
an NMA with five treatments and current optimal treatment k*= 4: the new treatment decision at the negative
and positive thresholds would be 2 and 3 respectively
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manner (equation (5)) from the set of possible solutions now given as follows: for kÅ =1
uakÆ,m=
−E.dakÆ/−ρ
[H]kÆ−1,m− [H]a−1,m
, for a∈{2, : : : ,K}\kÅ,
u1kÆ,m=
−E.d1kÆ/−ρ
[H]kÆ−1,m
, for a=1;
for kÅ=1
u1a,m=
−E.d1a/+ρ
[H]a−1,m
, for a∈{2, : : : ,K}:
More complex threshold analyses, e.g. for specific biases, may be undertaken by examining the
set of uab,m values from equation (6) (for an example, see Section 3.2.2).
2.3.2. Bias adjustment thresholds for the fixed effect model
For the FE model with conjugate normal prior distribution for the treatment effect parameters
d (equation (1)), the on-line appendix A.2 (see also Gelman et al. (2013), page 71) shows that
the posterior distribution is
d|y∼N{Σn.Σ
−1
d d0+X
TV−1y/,Σn} .8/
where the posterior covariance matrix is Σn= .Σ
−1
d +X
TV−1X/−1.
The threshold values are found by using equations (5) and (6), where the influence matrix is
H=ΣnX
TV−1 (on-line appendix A.3).
2.3.3. Bias adjustment thresholds for the random-effects model
The RE model (equation (2)) is typically specified with a prior distribution over the between-
studies standard deviation τ which, because of the hierarchical nature of the model, results in
a joint posterior distribution that generally has no closed form solution. One approach in this
situation would be to find bias adjustment thresholds numerically by iteratively changing the
data until the decision changes; this is likely to be very computationally expensive. However,
approximate algebraic bias adjustment thresholds can be obtained for the RE model by con-
sidering the between-studies variance to be known, fixed and unchanged after bias adjustment.
Sensitivity analyses may then be performed to assess how the thresholds change for various
values of τ2.
For theREmodel given in equation (2)with τ2 assumedknownandfixed, theon-line appendix
A.4 (see also Gelman et al. (2013), page 582) shows that the joint posterior distribution for
d and δ is (
d
δ
)∣∣∣∣y, τ2∼N
{
Σn
(
Σ
−1
d d0
V−1y
)
,Σn
}
,
Σn=
(
XTΣ−1
τ2
X+Σ−1d −X
T
Σ
−1
τ2
−Σ−1
τ2
X V−1+Σ−1
τ2
)−1
=
(
AÅ BÅ
BTÅ CÅ
)
,
.9/
where the posterior covariance matrix Σn is partitioned according to the dimensions of d and
δ. Under bias-adjusted data, it can be shown (on-line appendix A.5) that the joint posterior
mean becomes E˜.d/=E.d/+BÅV
−1βm. Following the same arguments as for the basic FE case
(on-line appendix A.3), the thresholds are given by equations (5) and (6) where the influence
matrix is now H=BÅV
−1.
The posterior covariance matrix Σn is the inverse of a block matrix and so can be calculated
explicitly (see Bernstein (2005), page 45); it is, however, more likely that Σn will have been
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estimated by using Bayesian software such as WinBUGS (Lunn et al., 2000). We can then
simply partition the posterior covariance matrix as in equation (9) to obtain BÅ.
2.3.4. Extended models with additional parameters
We may wish to add additional parameters to the basic FE and RE models (Sections 2.3.2 and
2.3.3), e.g. to include data as absolute effect measures (i.e. as one observation per study arm)
where a nuisance study level baseline parameter for arm 1 is included (Lu and Ades, 2006). We
denote the additional parameters byµ and give themanormal prior distributionµ∼N.µ0,Σµ/.
The simplest way to achieve this for the FE model is to extend the parameter vector to
γ=
(
d
µ
)
. The design matrix X is also extended to describe the model. The on-line appendix A.6
shows that we obtain the threshold equations (5) and (6), where the influence matrix is now
H= [ΣnX
TV−1]rows 1:K−1.
For the RE model, the additional parameters have an associated design matrix M, and we
impart further flexibility with a design matrix L for δ. The on-line appendix A.7 shows that the
thresholds are given by equations (5) and (6) with H= .BÅL
T+DÅM
T/V−1. Here, analogously
to equation (9), BÅ and DÅ are partitions of the posterior covariance matrix, corresponding to
the covariance of d with δ and of d with µ respectively.
2.3.5. Class effect random-effect model
Class effect models are often utilized in NMAs where treatment effects may be assumed ex-
changeable within discrete classes, e.g. based on common constituent compounds or modes
of action (Dominici et al., 1999; Mayo-Wilson et al., 2014). In such models, treatment effects
within the same class are assumed exchangeable and normally distributed as d|z∼N.Zz,Σd/,
with class effect parameters z and class design matrix Z assigning a class to each treatment.
The class effect parameters are given a normal prior distribution. Σd is the between-treatment
covariance matrix, which may specify a common within-class variance or different within-class
variances for each class. IfΣd is the zeromatrix then themodel is equivalent to fixed class effects.
To proceed analytically we assume that the between-studies variance τ2 is fixed, known and
invariant to bias adjustment (as with the RE model in Sections 2.3.3 and 2.3.4); we must also
make the same assumptions about thewithin-class variances (for the random class effectmodel).
In the on-line appendix A.8 we show that the influence matrix for an RE model including class
effects is identical to that in the extended RE case in Section 2.3.4; we may proceed exactly as
in the extended RE case despite the presence of class effects.
2.4. Bias adjustment thresholds at the contrast level
In clinical guideline development, assessment of the quality of evidence is often directed at the
entire body of evidence on a contrast rather than at individual studies. This is the method of
evidence classification that is used in, for example, extensions of GRADE to NMA (Puhan
et al., 2014; Salanti et al., 2014). We may therefore wish to examine the robustness of treatment
decisions to bias in the combined body of evidence at contrast level, rather than for individ-
ual studies. In some cases it may only be possible to obtain decision invariant thresholds at
the contrast level, i.e. when only the summary results (posterior means and covariance matrix
for all parameters) from an NMA are available. Alternatively the NMA may entail a complex,
hierarchical or otherwise analytically intractable model but where the joint posterior distri-
bution for the treatment effect parameters can be assumed to be approximately multivariate
normal.
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Our approach is to consider a hypothetical data set, consisting of a single independent data
point for each contrast where there is direct evidence, which when pooled by using an FE
NMA gives a posterior distribution that closely approximates the true posterior distribution as
reported by the original NMA. We are not suggesting independence of the original data, but
that the posterior distribution could have arisen (at least approximately) from an alternative set
of independent data points. Multiarm trials, REs and other features are therefore handled as
usual in the original NMA, and all correlations and uncertainty appropriately propagated into
the joint posterior distribution on which the contrast level threshold analysis is based. We show
that, to derive thresholds, we need only the covariance matrix of the hypothetical data, and not
the hypothetical data points themselves. We then proceed to derive thresholds as for the basic
FE model that was described in Section 2.3.2.
We consider a hypothetical data set consisting of single independent data points yab with
variances vab, representing the combined evidence on each contrast dab where there is direct
evidence, with multivariate normal likelihood y|d∼N.Xd,V/ where X is a design matrix and
V is diagonal with elements vab. We design the hypothetical data set so that pooling using an
FE NMA gives a posterior distribution N.ηˆ, Σˆ/ that closely approximates the true posterior
distribution N.η,Σ/ that is reported by the original NMA. Thresholds can then be derived as
for the basic FE model in Section 2.3.2.
A full derivation of the contrast level method is given in the on-line appendix A.9. We choose
V to solve Σ= Σˆ, where the covariance matrix of the reconstructed posterior distribution
is Σˆ= .Σ−1d +X
TV−1X/−1 (see Section 2.3.2). When the evidence network is complete (i.e.
every treatment is joined to every other by direct evidence), there is a unique exact solution;
otherwise an approximate solution is found by using non-negative least squares (Lawson and
Hanson, 1995). In the latter case, the performance of the approximation may be assessed by
examining the Kullback–Leibler divergence (Kullback and Leibler, 1951) of the reconstructed
posterior distribution from the true posterior distribution. Interpreting the Kullback–Leibler
divergence as a log-Bayes-factor, values less than 1 indicate negligible differences between the
reconstructed posterior from the true posterior and a good approximation, whereas values
greater than 3 indicate considerable differences and a poor approximation (Kass and Raftery,
1995).
Once the hypothetical likelihood covariancematrix has been reconstructed, the thresholds are
then evaluated as before by using equations (5) and (6) with the influence matrix H=ΣXTV−1.
Note that it would not be possible to re-evaluate the posterior means under the bias-adjusted
data to obtain k˜
Å
as we do not have the hypothetical data, but we can use the result of lemma 1
(on-line appendix A.1) to obtain the new optimal treatment efficiently, as before.
2.5. Thresholds for bias in multiple studies or contrasts
Thus far we have been concerned with the effects of bias adjustment for a single data point
at a time. However, we may wish to consider the effect of bias adjustment in multiple studies
or contrasts simultaneously, e.g. all the relative effects estimates from a multiarm study, or
perhaps multiple studies that are of concern. Such analyses are possible at both study and
contrast level, though they are more likely to be motivated by knowledge of individual trials
and their characteristics. Equation (7) shows how a general bias adjustment β would change
the posterior mean of the treatment effect parameters. We extend the approach that is taken in
the on-line appendix A.3 to let two elements of β be non-zero in equation (4), allowing for bias
adjustment in two data points ym1 and ym2 simultaneously. We end up solving K−1 equations
in two unknowns:
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Fig. 2. Example of thresholds lines in two dimensions for an NMA of five treatments with k*D4 ( , invariant
region about the origin (no bias adjustment)): any simultaneous bias adjustment .βm1 ,βm2 / to data points ym1
and ym2 which remains within the invariant region does not change the optimal treatment; at the boundary
of the invariant region formed by thresholds line βthresh
akÆ
the new optimal treatment is ˜k*Da
0= E˜.dakÆ/=E.dakÆ/+ .[H]kÆ−1,m1 − [H]a−1,m1/βm1 + .[H]kÆ−1,m2 − [H]a−1,m2/βm2 ,
∀ a∈{1, : : : ,K}\kÅ .10/
where m1 and m2 are the indices of the two data points to be bias adjusted. We see that,
instead of threshold points, we have K− 1 threshold lines in two dimensions. By rearrang-
ing equation (10) and using the definition of uakÆ,m from equation (6), we can use the set of
previously calculated uakÆ,m to arrive at the equation for each threshold line β
thresh
akÆ : βm2 =
uakÆ,m2 − .uakÆ,m2=uakÆ,m1/βm1 . The intersection of these threshold lines creates a bias invariant
region, e.g. as portrayed in Fig. 2 for an NMA of five treatments where the current optimal
treatment is kÅ=4.
It is simple both mathematically and computationally to carry on extending such a technique
to higher dimensions: allowing r N components of β to be non-zero results in r-dimensional
threshold hyperplanes βthreshakÆ with equations β
TwakÆ = 1 for a∈ {1, : : : ,K} \ k
Æ, where the ith
component of wakÆ is
[wakÆ ]i=
{
u−1akÆ,i if i∈{m1, : : : ,mr}
0 otherwise.
∀ i∈{1, : : : ,N}
However, beyond two (or possibly three) dimensions it becomes impossible to visualize and
analyse these threshold hyperplanes effectively and the resulting invariant hypervolume formed
by their intersection. As such, any analysis of simultaneous bias adjustment is probably best
approached in a targeted manner, identifying a small number of data points on which to focus
attention.
An alternative approach is to report the vectors βminakÆ =wakÆ=‖wakÆ‖
2 for a∈ {1, : : : ,K} \ kÅ
giving the point on each threshold hyperplane βthresh
akÅ which lies closest to the origin and so
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minimizes the amount of overall bias adjustment required to change the optimal treatment
decision to k˜
Å
=a.
3. Examples
We apply the threshold method to two examples: firstly, an NMA of thrombolytic treatments
(Caldwell et al., 2005) to demonstrate study and contrast level analyses on a simple FE model,
along with simultaneous bias adjustment in two data points; secondly, a large class effects
RE NMA comparing treatments for social anxiety (National Collaborating Centre for Mental
Health, 2013; Mayo-Wilson et al., 2014) to demonstrate the power of a contrast level analysis
when applied to complex models. Notes on practical computation are included in the on-line
appendix A.10. Code is provided at http://wileyonlinelibrary.com/journal/
rss-datasets along with an R package implementing the threshold method for general
use in the on-line supplementary materials.
3.1. Example: thrombolytics
Fig. 3 shows the network of treatment comparisons for K= 6 thrombolytic treatments based
on n=14 studies, taken from two systematic reviews (Boland et al., 2003; Keeley et al., 2003).
Previous work has shown that an FE model is appropriate for the data (Caldwell et al., 2005;
Dias, Welton, Sutton, Caldwell, Lu and Ades, 2013). All studies have two arms apart from one
with three, so the number of data points (log-odds-ratios (ORs)) is N=15.
3.1.1. Study level fixed effects analysis
An FE model was fitted to the data by using WinBUGS 1.4.3 (Lunn et al., 2000) and code
from Dias, Welton, Sutton, Caldwell, Lu and Ades (2013). The treatment effect parameters dk
are interpreted as the log-OR of mortality between treatment k and the reference treatment
1, and d1= 0. In this example the optimum treatment is the one which minimizes the log-OR
of mortality, here kÅ = argmink=1,:::,6 E.dk/= 3 (full results of the NMA are available in the
accompanying R package).
The results of each study and the study level threshold analysis are shown inFig. 4: the table on
the left-hand side displays the estimated log-OR from each study comparison along with a 95%
confidence interval (CI), and a decision invariant bias adjustment interval about the estimate,
Fig. 3. Thrombolytics example network, showing how the six treatments are connected by study evidence:
nodes represent treatments and edges show comparisons made by studies; numbers inside the nodes are
the treatment codings; numbers on the edges give the number of studies making that comparison; the bold
triangle is the loop formed by the three-arm study
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Study (Contrast) Log OR 95% Confidence Interval
34 (6 vs. 3)
35 (5 vs. 3)
11 (5 vs. 1)
1 (4 vs. 1)
1 (3 vs. 1)
6 (2 vs. 1)
36 (5 vs. 3)
5 (2 vs. 1)
10 (4 vs. 1)
8 (2 vs. 1)
2 (2 vs. 1)
9 (2 vs. 1)
7 (2 vs. 1)
4 (2 vs. 1)
3 (2 vs. 1)
0.01
0.03
−0.06
−0.05
−0.16
−0.03
−0.75
0.05
0.41
−0.56
−0.37
−0.73
−0.61
0.02
−0.90
(−0.12, 0.13)
(−0.10, 0.16)
(−0.24, 0.11)
(−0.14, 0.05)
(−0.25, −0.06)
(−0.10, 0.05)
(−1.70, 0.20)
(−0.04, 0.15)
(−0.89, 1.70)
(−1.52, 0.40)
(−1.44, 0.69)
(−1.83, 0.37)
(−1.88, 0.66)
(−1.62, 1.66)
(−2.58, 0.78)
6
5
5
4
6
2
5
2
4
2
2
2
2
2
2
(−0.00, 18.51)
(−0.03, 2.75)
(−0.20, 0.81)
(−0.15, 5.23)
(−1.19, −0.04)
(−0.26, 0.83)
(−3.99, 141.04)
(−0.31, 1.38)
(−29.48, 79.58)
(−36.85, 131.39)
(−44.98, 161.81)
(−48.53, 173.07)
(−63.88, 229.45)
(−105.85, 384.96)
(−112.15, 403.64)
5
6
2
5
4
6
6
6
5
6
6
Log Odds Ratio
6
−3 −2 −1 0 1 2
6
6
6
Invariant Interval and k
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Fig. 4. Study level forest plot, displaying invariant intervals for the thrombolytics example, sorted with smallest thresholds first (bold labels in the table
emphasize study estimates with short invariant intervals lying within the 95% CI; the optimal treatment without bias adjustment is k*D3):, log-OR; ,
95% CI; , invariant interval
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showinghowfar anybias adjustment canbemadebefore theoptimal treatment changes.Thenew
optimal treatments k˜
Å
are reported alongside either end of the invariant interval. The right-hand
side ofFig. 4 displays these graphically,with points and lines for estimated log-ORs and theirCIs
and shadedbands for the invariant regions.Wherea95%CIextendsbeyond the invariant interval
the study label is bold, indicating that the treatment recommendation is sensitive to the level of
imprecision in this study estimate. In this example, the treatment recommendation is sensitive
to the level of imprecision in studies 11 and 35 (k˜
Å
= 5) and study 34 (k˜
Å
= 6). For example,
the estimated log-OR of 0.01 for treatment 6 versus 3 in study 34 has an invariant interval of
(−0:00, 18.51); a change to the log-OR of only−0:01 in favour of treatment 6 (either due to bias
adjustment, or simply random sampling error) is enough to change the optimal treatment from
kÅ=3 to k˜
Å
=6. Looking at the network of treatments (Fig. 3), this sensitivity is not surprising.
Treatment 6 is only compared directly with treatment 3, and only in study 34, which found
no evidence of a significant difference between the two treatments (the 95% CI for the log-OR
contains zero). Since kÅ=3, adjusting the log-OR to be in favour of treatment 6 means that the
network of evidence behind treatment 3 now points to k˜
Å
=6. Similarly, changes of −0:06 and
−0:14 to the treatments 5 versus 3 and 5 versus 1 comparisons of studies 35 and 11 respectively
both result in k˜
Å
= 5 becoming optimal. Other studies may be biased beyond the range of the
95%CI; ourmethod highlights that the treatment recommendationmay be sensitive to plausible
bias adjustments in studies 1, 5 and 6, each with thresholds less than 0.5 on the log-OR scale.
All studies with plausibly small thresholds should be assessed for risk of bias, e.g. by using
GRADE (Guyatt et al., 2011) or the Cochrane risk-of-bias tool (Higgins et al., 2011), and the
thresholds and invariant intervals interpreted in light of the expected magnitude and direction
of bias, e.g. novelty bias favouring a new treatment. The metaepidemiological literature on the
empirical evidence for bias is likely to help to determine plausiblemagnitudes for biases (Savovic
et al., 2012a). In the remaining studies, our method reveals that no changes—no matter how
large—can ever plausibly lead to changes in the treatment recommendation, particularly studies
2–4 and 7–10, since the bias adjustment thresholds are infeasibly large on the log-OR scale.
3.1.2. Contrast level analysis
We also perform a contrast level analysis to examine sensitivity to changes in the aggregate
bodies of evidence on each contrast. We do not need the original data to do this; we use only the
posterior means and covariance matrix from the joint posterior distribution of the treatment
effect parameters d= .d2, : : : ,d6/
T. We treat the posterior distribution as if it arose from an
NMA on seven independent data points y= .y12, y13,y14,y15,y34, y35,y36/
T—the number of
direct comparisons in the treatment network (i.e. the edges in Fig. 3). Each data point yab
represents the combined direct study evidence on a treatment contrast dab.
Following the methods in Section 2.4, we construct an approximate hypothetical likelihood
by using non-negative least squares—see the on-line appendix A.11. The Kullback–Leibler
divergence of the reconstructed posterior distribution from the true posterior distribution is
very small at 6:76×10−5, indicating that the hypothetical data are a good approximation.
Fig. 5 presents results of theNMAand the contrast level analysis, which echoes the study level
analysis. Notably the thresholds for contrasts where there is a single two-arm study making the
comparison (treatments 6 versus 3 and 5 versus 1) match almost exactly with the thresholds for
the corresponding studies in the study level analysis (Section 3.1.1), as expected. Furthermore,
we clearly see the effects of bias adjustment on entire bodies of evidence in comparison with
the study level approach: individually, studies making the treatments 2 versus 1 comparison
have little influence on the treatment decision, shown by wide invariant intervals (Fig. 4); when
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Contrast Log OR 95% Credible Interval
2 vs. 1
3 vs. 1
4 vs. 1
5 vs. 1
4 vs. 3
5 vs. 3
6 vs. 3
−0.00
−0.15
−0.04
−0.10
0.11
0.04
0.01
(−0.06, 0.06)
(−0.23, −0.06)
(−0.13, 0.05)
(−0.22, 0.02)
(−0.00, 0.21)
(−0.07, 0.15)
(−0.12, 0.13)
2
6
4
5
4
5
6
(−0.14, 0.51)
(−1.56, 0.05)
(−0.24, 0.48)
(−0.25, 0.78)
(−0.12, 3.85)
(−0.02, 2.69)
(0.00, 18.44)
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Fig. 5. Contrast level forest plot, displaying invariant intervals for the thrombolytics example (bold labels in the table emphasize contrast estimates with
short invariant intervals lying within the 95% credible interval; the optimal treatment without bias adjustment is k*D3): , log-OR; , 95% credible
interval; , invariant interval
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the evidence from these studies is considered collectively for bias adjustment, the combined
invariant interval becomes narrower. Indeed, a combined bias adjustment of −0:14 in favour
of treatment 2 may be plausible. Note here that the black lines in Fig. 5 correspond to the 95%
credible intervals for each contrast estimate resulting from the NMA, instead of CIs for each
study estimate as in the study level analysis (Fig. 4).
The threshold analysis gives very small thresholds for the combined evidence on treatment
contrasts 5 versus 3 and 6 versus 3, which is symptomatic of the lack of evidence for significant
differences between these treatments. A likely treatment decision in such a scenario (in the
absence of issues surrounding cost or adverse events) would therefore be to recommend any of
these three treatments.
3.1.3. Simultaneous bias adjustment in two data points
We shall now consider analysing bias adjustment in two data points simultaneously. Such an
analysis is possible at both study and contrast level, though it is more likely to be motivated by
knowledge of individual trials and their characteristics; thus we shall return to the study level
scenario for this example. In the thrombolytics data set, study 1 was a three-armed study com-
paring treatments 1, 3 and 4, resulting in two log-OR estimates against the reference treatment
1. The two log-ORs are not independent, and so if bias adjustment is required it is possible
that both estimates will need to be bias adjusted together—if the trial failed to blind patients,
for example. Fig. 6 presents the invariant region for simultaneous bias adjustments in the two
log-ORs estimated by study 1, formed by the polygon of intersecting threshold lines about the
origin, which can either be closed (threshold lines in every direction) or open (bias adjustment in
some direction will never cross a threshold line). In this example, three threshold lines form an
invariant region for bias adjustment, with new optimal treatments at the thresholds kÅ=4, 5, 6.
The points where the boundaries of the invariant region intersect the axes correspond to the
one-dimensional invariant intervals that were presented in Fig. 4, since setting one of the two
bias adjustments to 0 returns us to analysing a bias adjustment in one data point only. Of par-
ticular interest are the threshold lines for k˜
Å
= 4 and k˜
Å
= 5 which lie closest to the origin. In
the one-dimensional case we saw that, individually, bias adjustments of 0.12 in the log-OR of
treatment 3 versus 1 or −0:11 in the log-OR of treatment 4 versus 1 were needed to change the
optimal treatment to k˜
Å
=4, and a bias adjustment of 5.28 in the log-OR of treatment 4 versus
1was needed to change the optimal treatment to k˜
Å
=5 (Fig. 4). Now, allowing both estimates to
be bias adjusted simultaneously, we see that it is possible to arrive at k˜
Å
=5 with much smaller
amounts of bias adjustment than this; for example with bias adjustments of just 0.14 to the
treatment 3 versus 1 log-OR and 0.02 to the treatment 4 versus 1 log-OR we cross the invariant
threshold and would recommend treatment 5.
3.2. Example: social anxiety
We now consider a more complex example where analysis is greatly simplified by using the
contrast level approach. Fig. 7 shows the network for an NMA of 41 interventions for social
anxiety from100 studies (NationalCollaboratingCentre forMentalHealth, 2013;Mayo-Wilson
et al., 2014). The original analysis uses an REmodel which includes class effects for 17 different
treatment classes and a secondary network of studies for a regression calibration on recovery.
No single common outcomemeasure was used across the studies included, so instead treatment
effects were transformed into standardized mean differences (SMDs) for NMA. Table A1 in the
on-line appendix A.12 lists the treatment codes and classes, and full results of the NMA are
available in the accompanying R package.
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Fig. 6. Invariant region formed from threshold lines for bias adjustment to the two relative effect estimates
from study 1 ( , invariant region): the new optimal treatments on the boundary are indicated by ˜k*; optimal
treatment without bias adjustment is k*D3
3.2.1. Contrast level analysis
Despite the complexity of the original analysis, a contrast level threshold analysis is straightfor-
ward.We consider the joint posterior distribution as if it arose from anNMAon 84 independent
data points, each representing the aggregate direct evidence that is available on a single treat-
ment contrast. Following the methods in Section 2.4, we construct an approximate hypothetical
likelihood by using non-negative least squares. The fitted hypothetical likelihood covariance
matrix includes a single infinite variance for one contrast (treatment 7 versus 1), meaning that
the direct evidence on this contrast is estimated to have no influence on the posterior distribu-
tion. The Kullback–Leibler divergence of the reconstructed posterior distribution from the true
posterior distribution is 1.55, indicating that the hypothetical data are a reasonable approxima-
tion (interpreted as a log-Bayes-factor, greater than 1 but less than 3).
Owing to the large number of contrasts, Fig. 8 shows only the results of the threshold analysis
for contrasts with thresholds of less than 2 SMDs. The optimal treatment under the original
analysis is kÅ = 41, group cognitive behavioural therapy with phenelzine. No contrasts have
invariant intervals which lie inside the 95% credible interval, meaning that the treatment recom-
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Fig. 7. Social anxiety treatment network: nodes represent treatments and edges show study comparisons;
numbers around the edge are the treatment codings; treatment classes are indicated by the braces (some
classes contain a single treatment only); treatment 1 is waitlist, treatment 2 is pill placebo and treatment 3 is
psychological placebo; Table A1 in the on-line appendix A.12 lists the treatment codes and classes
mendation is robust to the level of imprecision in the contrast level data. The smallest threshold
is a positive change of 0.46 in the estimate of−0:88 SMD for the treatment 41 versus 31 contrast
(the upper limit of the corresponding invariant interval is−0:88+0:46=−0:42), at which point
treatment 36 (cognitive therapy) becomes optimal. Cohen (1988) considered an SMD of more
than 0.8 to be large in the context of behavioural sciences; all except five thresholds are larger
than this, and for each of these the new optimal treatment is treatment 36.Note that some invari-
ant intervals are open on one side (indicated by ‘NT’) as there is no threshold in this direction;
for these contrasts, a bias adjustment in this direction will never change the treatment decision.
An important observation from this analysis is that the treatment recommendation is insensitive
to changes in the combined evidence on the large majority of contrasts. Rather than performing
a long and laborious qualitative assessment of all 84 contrasts and 100 studies, attention can be
focused on the smaller number of contrasts (e.g. the five studies with thresholds smaller than
0.8 SMD) where plausible adjustments to the data may cause a change in treatment recommen-
dation. Risk of bias assessments should be performed for these contrasts, and the thresholds
and invariant intervals interpreted in light of the magnitude and direction of any potential bias.
3.2.2. More complex analyses: pharmacological and psychological treatment bias
The methods that were described in Section 2 are easily extended to more complex decision
rules and bias adjustment scenarios, simply by manipulating the set of uakÆ,m values. Here,
we have considered the effects of adjusting for a potential common bias (at the contrast level)
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Contrast SMD 95% Credible Interval
41 vs. 31
41 vs. 23
36 vs. 1
36 vs. 16
39 vs. 18
38 vs. 21
36 vs. 24
41 vs. 2
25 vs. 24
11 vs. 2
34 vs. 1
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12 vs. 2
32 vs. 30
23 vs. 2
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17 vs. 2
13 vs. 2
31 vs. 8
37 vs. 30
21 vs. 2
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19 vs. 2
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18 vs. 2
8 vs. 1
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Fig. 8. Contrast level forest plot for the social anxiety example showing results of the threshold analysis, sorted with smallest thresholds first (only contrasts
with a threshold less than 2 SMDs are shown here for brevity; the complete results can be found in the Web supplementary material; the optimal treatment
without bias adjustment is k*D41); NT, no threshold;, SMD; —, 95% credible interval; , invariant interval
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Fig. 9. (a) Invariant interval for all pharmacological treatments against an inactive control, considered to
be bias adjusted by the same amount, and (b) invariant interval for all psychological treatments against an
inactive control, considered to be bias adjusted by the same amount; the optimal treatment without any bias
adjustment is k*D41
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Fig. 10. Invariant region ( ) for simultaneous adjustments for common biases in all psychological and all
pharmacological treatments: the new treatment recommendation at the boundary is shown as ˜k*; the optimal
treatment without bias adjustment is k*D41
among all pharmacological treatments (including combination therapies) and similarly among
all psychological treatments. To do this, note that the influence of a common bias to a set of
data points {ym :m∈M} (e.g. the pharmacological treatment contrasts versus inactive) is equal
to the sum of the influences for each individual data point. Thus, the set of possible threshold
solutions for a common bias is {uakÆ,M :a∈{1, : : : ,K}\k
Å}, where
uakÆ,M=
−E.dakÆ/∑
m∈M
.[H]kÆ−1,m− [H]a−1,m/
=
( ∑
m∈M
u−1akÆ,m
)−1
:
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As before, the thresholds are then found by taking the smallest positive and negative solutions
from this set.
The results of these analyses are shown in Fig. 9. In each case, at the smallest threshold, treat-
ment 36 becomes optimal: with an adjustment of 0.67 SMD for all pharmacological treatments
compared with inactive control (i.e. reducing their efficacy), or with an adjustment of −0:66
SMD for all psychological treatments compared with an inactive control (i.e. increasing their
efficacy). The magnitude of these thresholds is large (Cohen, 1988)—probably much larger than
any plausible common bias. We might also consider the effects of adjusting for these common
biases simultaneously by examining the set of uakÆ,m values. The resulting two-dimensional in-
variant region is shown in Fig. 10. The size of the invariant region would probably reassure
decision makers that adjustment for common pharmacological and/or psychological treatment
effect biases (if they exist) would not affect the treatment recommendation.
4. Discussion
The threshold method that is presented in this paper enables researchers and decision makers to
quantify the robustness of their conclusions to potentially biased evidence. Like all sensitivity
analyses, it is useful for decision makers to know how robust their decision is to variations in
assumptions and in the evidence inputs, especially if decisions are likely to be controversial,
or when the quality of evidence is likely to be questioned. Current approaches based around
the GRADE framework (Puhan et al., 2014; Salanti et al., 2014) give a thorough qualitative
evaluation of the quality of evidence behind such decisions, but they fall short of describing the
influence on treatment recommendations of any bias in the evidence. Providing bias adjustment
thresholds and invariant regions can attest to the robustness of conclusions despite poor quality
evidence, or it can highlight areas where the evidence should be carefully assessed for bias
since bias adjustments of plausible magnitude could change the optimal treatment decision.
Although our method gives quantitative results, their interpretation still requires qualitative
judgements to determine which evidence might plausibly be biased and to what extent; the
metaepidemiological literature on the empirical evidence for bias is likely to be helpful once
potential biases have been identified in a risk of bias assessment (Savovic et al., 2012a). It is
important to note that, although we highlight where a decision is sensitive to imprecision in
the evidence when thresholds lie inside the CI or credible interval, it is entirely possible for
larger bias adjustments to be plausible; for example, large studies yielding precise estimates
may be biased beyond the range of their 95% CI. Although we have discussed only NMA of
RCTs, the threshold method applies equally to analyses incorporating observational evidence;
however, the potential for bias is much greater when including non-randomized evidence, and
the direction and magnitude of bias is difficult to predict.
It must be clear that threshold analyses do not seek to test for the presence or absence of bias;
nor do they make any assumptions about the source, type or expected magnitude or direction
of any bias. Rather, if any such bias was present, then subsequent adjustment would only alter
the treatment decision if it were larger than the given thresholds. Knowledge of the likely nature
of possible biases should be used in the planning and—most importantly—interpretation of
threshold analyses.
Threshold analysis has previously been proposed by Caldwell et al. (2016), using a numerical
method to derive thresholds based on a two-stage Bayesian NMA. A particular feature of the
method that is proposed in this paper is that it starts from the one-stage Bayesian posterior
distribution of relative treatment effects and manipulates it algebraically, rather than iteratively
modifying the data.Not only can algebraic solutions be reached almost instantaneously by using
Sensitivity of Treatment Recommendations to Bias 863
matrix operations rather than lengthy and computationally expensive numerical techniques, but
also this confers considerable flexibility; in practice, treatment recommendations are often based
on complex models with multiple types of data input which would be difficult to fit into the
two-stage framework. Furthermore, the original data are not required for the threshold analysis
to be performed, provided that posterior means and the covariance matrix of the parameters
are available. Although not frequently published at present, this level of summary data is likely
to be much easier to obtain on request than the full original data set; this significantly widens
the scope of threshold analysis, compared with numerical methods.
Anextensionof thiswork is to embed the thresholdmethod intoaprobabilisticCEA(Doubilet
et al., 1985; Critchfield and Willard, 1986; Dias et al., 2013b), where the optimal treatment is
found not by maximizing the posterior expected treatment effect as in equation (3), but by
maximizing the posterior expected value of some net benefit function instead. A CEA seeks
to weigh up the improvements in quality of life and life expectancy against the total costs for
each treatment regimen, and this is achieved by the use of a net benefit function (Stinnett and
Mullahy, 1998). Such analyses are used extensively by reimbursement agencies and threshold
analysis would be useful to determine how bias adjustments can affect the outcome of a CEA.
When the net benefit function is linear in treatment efficacy (or can be approximated as such),
the threshold equations (6) can be easily transformed onto the net benefit scale. However,
CEA models can be complex and often involve net benefit functions that are non-linear; as
such it would be useful to extend the threshold methodology to deal with non-linear decision
functions.
Other decision rules besides maximum efficacy or net benefit may be considered, e.g. recom-
mending any active treatment if better thanplacebo, recommending a groupof treatmentswhose
efficacies are clinically equivalent (e.g. within some minimum clinically important difference or
non-inferioritymargin) or restricting a recommendation to currently available treatments.More
complex threshold analyses are also possible, e.g. to examine generic bias in a class of treatments
or studies sharing given characteristics. All of these analyses are possible directly by examining
the set of values uab,m (see equation (6)), giving the amount of adjustment to data point ym
which would see the posterior expectation of the contrast between treatments a and b change
sign (so treatment preference between a and b switches).
Derivationof algebraic thresholds for theREmodel is hinderedby theanalytic intractabilityof
the joint posterior distribution when the between-studies variance is given a prior distribution;
instead we make the assumption that this variance is fixed and known so that conjugacy is
preserved. This assumption should be tested by sensitivity analyses substituting plausible values
of τ2, e.g. from the upper and lower limits of the 95% credible interval that is obtained from
the NMA or from predictive distributions that are derived from similar meta-analyses (Rhodes
et al., 2015; Turner et al., 2015). There is empirical evidence that heterogeneity is greater in
biased evidence bases (Savovic et al., 2012a,b), so it might be expected that τ2 would reduce
after adjusting for bias (possibly beyond the lower credible limit).
Further applications of the threshold method are to metaregression and bias adjustment
models (Dias et al., 2013b). The approachwould follow from Section 2.3.4, where the additional
parameters are regression covariates. Particular care should be taken to define an appropriate
decision rule and in the interpretation of the treatment effect parameters since decisions can
be different at different covariate values. The interpretation of the thresholds in this case is in
terms of the adjustment for residual biases that are not accounted for in the model.
We have seen that the influence matrix H mapping the data y onto the posterior mean of
the treatment effect parameters E.d/ is central to the derivation of thresholds and describes
how changes in individual data points affect the posterior means of the basic treatment effect
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parameters. The role of a related quantity, the hat or contributions matrix, has been highlighted
by several researchers previously in the context of influence analysis (Konig et al., 2013; Krahn
et al., 2013; Salanti et al., 2014). The hat matrix describes how changes in individual data points
affect the predicted values (as opposed to the treatment parameters), and in the basic FEmodel
is derived from the design and influence matrices as XH. Krahn et al. (2013) and Konig et al.
(2013) used the hat matrix to visualize the ‘flow of evidence’ in an NMA and to analyse and
detect inconsistency, which Salanti et al. (2014) utilized within the context of GRADE applied
to NMA.
A key contribution of this paper has been the reconstruction of the influence matrix (and
therefore the hat matrix) from the Bayesian posterior distribution. This allows considerable
flexibility because, in practice, treatment recommendations may be based on complex models,
e.g. including class effects, andmay incorporate several typesofdata.The social anxiety guideline
(National Collaborating Centre for Mental Health, 2013), for example, incorporates data on
both response and recovery rates, and synthesizes trials reporting either ORs or outcomes on
continuous scales. It is, of course, the need for flexible computation methods in the face of
irregular and complex data that has made Bayesian Markov chain Monte Carlo sampling the
method of choice in practical applications (Dias et al., 2013a).
Although we have derived results in a Bayesian context, the threshold method applies equally
to NMAs that are performed within a frequentist framework. The influence matrix H can be
written down for many frequentist estimation routines: for example, the maximum likelihood
estimate for the treatment parameters in an FE model is of the form dˆ= .XTV−1X/−1XTV−1y,
so the influence matrix is H= .XTV−1X/−1XTV−1, and we continue with equation (6) to derive
thresholds as usual. In this case the result can also be reached by considering the frequentist
framework as a special case of the Bayesian framework with the prior precision matrix Σ−1d
equal to 0; for other estimation routines the correspondence is not exact but may be a useful
approximation if the influence matrix has no closed form.
One practical limitation of the threshold method is that there is no satisfactory way to display
the results of simultaneous bias adjustments in more than three contrasts or data points. As
we have shown in Section 2.5 the problem lies not with deriving bias adjustment thresholds in
higher dimensions but in visualizing and interpreting them. We have given examples of how to
visualize invariant regions in two dimensions (e.g. Fig. 6 in Section 3.1.3), and a similar ap-
proach is possible in three dimensions. For more than three contrasts or data points, a graphical
representation of this kind is not possible, making interpretation difficult. However, in practice,
if bias adjustment is to be considered for a large number of studies, it may be preferable to esti-
mate the study level bias adjustment within the hierarchical NMA analysis, either by regression
(Dias et al., 2010; Salanti et al., 2010; Naci et al., 2014) or by giving bias terms informative
priors based on expert opinion (Turner et al., 2009; Welton et al., 2009; Dias et al., 2010). A
potential avenue for future research into the effects of multiple simultaneous bias adjustments
lies with the influence matrix. By examining this matrix it should be possible to identify whether
bias adjustment in a given combination of data points may lead to wider invariant intervals, due
to the influences of multiple data points partially cancelling out, or smaller invariant intervals,
due to the combined influence increasing additively.
Importantly, threshold analysis of complex, hierarchical or otherwise atypical NMAmodels
may always be performed at the contrast level, provided that the joint posterior distribution of
the treatment effect parameters is available (either first hand from an analysis, or sufficiently
reported in a publishedNMA), and that this joint posterior distribution is at least approximately
normal. Under such conditions we can apply the methods that were proposed in Section 2.4
to derive bias adjustment thresholds and invariant intervals, regardless of the manner in which
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the joint posterior distribution arose. As such, the threshold method proposed is applicable to
a wide range of situations that may be encountered by decision makers and has the potential
to focus discussion on the risk of bias in particular studies or comparisons to which the final
treatment recommendation is most sensitive.
5. Supplementary materials
5.1. Appendices
All appendices are contained in a separate on-line document providing technical derivations,
statements and proofs of theorems and lemmas, and notes on computation.
5.2. Computer code
An R package nmathresh is provided in the on-line material that implements the threshold
method, and the R code and data that were used to perform the example analyses are available
from
http://wileyonlinelibrary.com/journal/rss-datasets
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